Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2539378 | 0.93 | ADORA1 (0.56) | ADORA1ADORA2AADORA2BGLAADORA3 | |
| SCHEMBL2538825 | 0.90 | ADORA1 (0.53) | ADORA1ADORA2AADORA2BGLAADORA3 | |
| SCHEMBL8180993 | 0.89 | ADORA1 (0.53) | ADORA1ADORA2AADORA2BGLAADORA3 | |
| SCHEMBL2541029 | 0.89 | ADORA1 (0.59) | ADORA1ADORA2AADORA2BGLAADORA3 | |
| SCHEMBL2545534 | 0.89 | ADORA1 (0.53) | ADORA1ADORA2AADORA2BGLAADORA3 | |
| SCHEMBL2537627 | 0.89 | ADORA1 (0.57) | ADORA1ADORA2AADORA2BGLAMAOB | |
| SCHEMBL2540207 | 0.89 | ADORA1 (0.53) | ADORA1ADORA2AADORA2BGLAADORA3 | |
| SCHEMBL2542723 | 0.88 | ADORA1 (0.51) | ADORA1ADORA2AADORA2BGLAADORA3 | |
| SCHEMBL2540252 | 0.88 | ADORA1 (0.67) | ADORA1ADORA2AADORA2BGLAADORA3 | |
| SCHEMBL2542178 | 0.85 | ADORA1 (0.49) | ADORA1ADORA2AADORA2BGLAADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1939197-A1 | 8-ethinylxanthine derivatives as selective A2A receptor antagonists | SCHWARZ PHARMA AG (DE) | 2008-07-02 | — | — | EP | disclosed |